Cefamar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefamar

What is Cefamar?

Cefamar is a prescription antibiotic medication used to treat a variety of bacterial infections. It belongs to a class of drugs known as second-generation cephalosporins. These medications work by interfering with the formation of the bacterial cell wall, which eventually leads to the destruction of the bacteria.

Therapeutic Class and Mechanism

As a cephalosporin antibiotic, Cefamar is categorized as a beta-lactam. It is designed to be effective against a broad spectrum of bacteria, including both Gram-positive and certain Gram-negative organisms. By binding to specific proteins within the bacterial cell wall, the medication prevents the bacteria from stabilizing their structure, making it impossible for the organisms to survive and multiply.

Common Uses

Cefamar is typically utilized to manage infections in different parts of the body. Because of its broad-spectrum activity, it is often used for the following conditions:

  • Respiratory Tract Infections: Including infections of the throat, tonsils, and lungs.
  • Ear, Nose, and Throat Infections: Such as otitis media (middle ear infections) and sinusitis.
  • Urinary Tract Infections: Addressing bacterial growth within the bladder or kidneys.
  • Skin and Soft Tissue Infections: Treating localized bacterial infections of the skin.
  • Lyme Disease: In certain early stages, it may be used to manage the systemic bacterial infection caused by tick bites.

Chemical Composition

The active ingredient in Cefamar is cefuroxime (often in the form of cefuroxime axetil for oral administration). This compound was developed to provide greater resistance to the enzymes (beta-lactamases) that some bacteria produce to defend themselves against penicillin-type antibiotics. This chemical stability allows Cefamar to remain effective against certain strains of bacteria that might otherwise be resistant to older antibiotics.

Regulatory References

  1. NIH - Cefuroxime Information
  2. MedlinePlus - Cefuroxime
  3. FDA-approved and common uses

What side effects are possible with Cefamar?

Possible side effects and safety information

Note on Regulatory Status

The product name Cefamar is not officially registered as a unique drug entity with major governmental drug regulatory authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is, however, identified in some documentation as a brand name for the generic antibiotic Cefuroxime (a second-generation cephalosporin).

Since an official, dedicated regulatory label for a product named Cefamar cannot be cited, the safety profile is derived from the established governmental safety documents for the active ingredient, Cefuroxime, and the broader Cephalosporin class of antibiotics.


Official Safety Profile (Based on Cefuroxime and Cephalosporin Class)

Adverse Reaction Scope

Classification Side Effects (Representative Examples)
Common Headache, dizziness, diarrhea, nausea, vomiting, stomach pain, and transient increase in liver enzymes.
Serious / Clinically Significant Hypersensitivity reactions (severe allergic reactions, including anaphylaxis); severe skin reactions; Clostridioides difficile-associated diarrhea (CDAD) or pseudomembranous colitis; increased risk of bleeding due to effects on blood clotting (e.g., elevated INR); seizures.
System-Organ Classes (SOC) Gastrointestinal System Disorders, Immune System Disorders, Nervous System Disorders, Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, and Blood and Lymphatic System Disorders.

Safety-Related Considerations

  • Hypersensitivity: Official labels carry warnings regarding severe and occasionally fatal hypersensitivity reactions. Cross-sensitivity with penicillin-allergic patients has been established and requires caution before use.
  • Renal Impairment: Cephalosporins are associated with seizure activity, particularly in patients with kidney impairment who do not receive appropriate dose adjustments. Caution is advised in patients with a history of seizure disorders.
  • Superinfection: Prolonged use of antibiotics, including Cefuroxime, may lead to overgrowth of non-susceptible organisms, resulting in fungal or bacterial superinfection, including CDAD.
  • Population-Specific Notes: Caution is advised in patients with a history of gastrointestinal disease, particularly colitis.

The official safety documents structure the understanding of risks by categorizing them based on frequency and severity, with serious warnings highlighted to ensure appropriate risk management in vulnerable populations, especially those with kidney impairment or known allergies to beta-lactam antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information describes overdose with Cefamar (cefuroxime) as primarily involving the Central Nervous System (CNS), which can lead to severe neurological manifestations.

Documented Overdose Manifestations

Feature Official Regulatory Statement
Documented Manifestations Symptoms of cerebral irritancy, including convulsions (seizures), obtundation, stupor, and encephalopathy.
Risk Note The risk of severe neurotoxicity is significantly increased in individuals with impaired renal function due to reduced drug clearance.

Required Emergency Actions

Immediate medical attention is mandated for a suspected overdose or if severe symptoms occur, exactly as described in governmental health guidance:

  • Call emergency services (911 or equivalent) if the victim has collapsed, is having a seizure, has trouble breathing, or cannot be awakened.
  • Contact a certified Poison Control Center immediately upon suspected overdose.

Overdose Management

No specific pharmacological antidote is known for cefuroxime. The management strategy is based on supportive care and procedural intervention. Procedures such as hemodialysis and peritoneal dialysis are officially documented as measures that can effectively reduce the concentration of cefuroxime in the bloodstream in severe cases.

Therapeutic Uses of Cefamar

Cefamar (cefuroxime) is a relevant therapeutic option applied across domains where additional symptomatic support is needed. Cefamar is applicable within clinical settings that involve acute or disruptive symptom patterns, offering supportive relief that helps ease the overall symptom burden. It plays a role in managing acute episodes such as pneumonia, bronchitis, otitis media (ear infection), sinusitis, and specific infections, including early-stage Lyme disease and uncomplicated gonorrhea.


Quick Fact: Relief for Acute Discomfort

Feature Detail
Symptoms Addressed Fever, localized pain, inflammation, functional strain
Benefit Goal Contributes to easing the overall symptom load
Use Context Acute infectious episodes, surgical prophylaxis

Symptom Management and Therapeutic Support

Cefamar is relevant in contexts marked by increased discomfort or tension, often used during phases when symptoms become more noticeable. It may assist with managing symptoms related to physical discomfort, such as persistent sore throat, chest discomfort, and localized earache or urinary pain. Its use in these domains assists with maintaining functional stability and supports the patient during difficult episodes by easing distress. Cefamar is also commonly used as a prophylactic measure—applied in scenarios where short-term symptomatic assistance is needed to support general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Cefamar (cefuroxime) eligibility is strictly defined by regulatory guidelines concerning allergies, age, and pre-existing medical conditions. Official documentation determines who may use the medicine and who must be excluded.

Contraindications and Non-Eligibility

The absolute restriction for using Cefamar is a documented severe allergy or hypersensitivity to cefuroxime, any cephalosporin antibiotic, or any other beta-lactam antibiotic (such as penicillin). Patients with this history are strictly contraindicated.

Population Group Eligibility Status
Allergy to Cephalosporins / beta-lactams Contraindicated (Must Not Use)
Infants under 3 months (Oral Form) Use Not Established
Adults and Children ge 3 months Allowed

Conditional Use Requirements

Certain health statuses require conditional use or formulation limits:

  • Renal Impairment: Eligibility is permitted for patients with impaired kidney function, but the official label mandates an adjustment to the dosing interval for those with severe impairment (Creatinine Clearance < 30 mL/min).
  • Phenylketonuria (PKU): Patients with PKU are typically restricted from using the oral suspension formulation, as it contains phenylalanine. This restriction does not apply to the tablet form.
  • Pregnancy and Lactation: Use during pregnancy is documented as conditional and only if the clinical need is clear. The medicine is present in human milk at low levels, requiring weighing the benefits of breastfeeding against potential infant effects, as stated in official guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefamar (cefuroxime) has officially documented interactions that primarily affect its concentration in the body or interfere with clinical testing procedures, as outlined in regulatory information.


Pharmacokinetic and Exposure-Altering Interactions

Classification Interacting Substance/Class Official Interaction Statement
Reduced Clearance Probenecid Co-administration is not recommended; it increases systemic exposure by inhibiting renal tubular secretion.
Reduced Bioavailability Gastric Acidity-Reducing Agents (Antacids, H2 blockers, PPIs) Lower the bioavailability of the oral form (cefuroxime axetil).
Reduced Efficacy Oral Contraceptives May lower the efficacy due to effects on gut flora.

Procedural and Analytical Interactions

Constraint Interacting Product Resulting Effect
Timing Requirement Gastric Acidity-Reducing Agents Temporal separation is required to mitigate the documented reduction in bioavailability.
Analytical Interference Copper Reduction Tests (Urine Glucose) Leads to a false-positive result for glucose.
Analytical Interference Ferricyanide Tests (Blood/Plasma Glucose) Leads to a false-negative result for glucose.

The regulatory profile highlights that co-administration with probenecid is formally restricted to avoid elevated drug levels, which are the result of reduced renal clearance. Separately, the oral form's absorption is sensitive to pH changes, requiring the administration of acid-reducing medicines to be spaced out to prevent lowered concentrations. The profile is further structured by explicit warnings about interference with specific, non-enzymatic glucose testing methods.

Mechanism of Action

Irreversible Inhibition of Cell Wall Enzymes

Cefamar exerts its primary action by targeting and irreversibly inhibiting Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the rigid protective wall. This molecular interference blocks the transpeptidation step of peptidoglycan synthesis, which is the final stage of the bacterial cell wall assembly pathway.


Disruption of Bacterial Structural Integrity

The inhibition of the cell wall synthesis pathway leads directly to the disruption of the bacterial cell's structural integrity. Because the weakened wall cannot withstand the high internal osmotic pressure, the bacterial cell swells and ruptures (lysis). The mechanism results in the elimination of the microbial burden.


Selective Bactericidal Action

Cefamar is classified as bactericidal, meaning it actively destroys the pathogen rather than merely arresting its growth. This is achieved through a mechanism highly selective for unique bacterial structures, having minimal interaction with host human cells. The selectivity and direct killing pattern are constrained only by the bacteria's ability to evolve counter-mechanisms, such as the production of beta-lactamase enzymes, which inactivate the drug. The mechanism achieves a rapid decline in the viable bacterial population.

Dosage and Administration Information

How to Use Cefamar

Cefamar (cefuroxime) usage is strictly governed by its administration route, fixed dosing schedule, and required administration conditions, all detailed within official prescribing labels. The medication is available in two main forms that dictate its route of use: Cefuroxime axetil for oral administration (tablets or suspension) and Cefuroxime sodium for parenteral (intravenous or intramuscular) administration.


Official Administration Guidelines

Category Official Administration Guideline
Route of Administration Oral (tablets/suspension) and Parenteral (IV/IM injection).
Standard Dosing Frequency Oral forms are typically scheduled to be taken every 12 hours (twice daily). Parenteral administration is often fixed at every 8 hours (three times daily) for systemic infections.
Timing in Relation to Meals The oral suspension must be taken with food to ensure correct drug absorption. Oral tablets may be taken independently of meals.
Course Duration The length of treatment is fixed by the specific infection being addressed, often lasting 5 to 10 days for most acute conditions, or up to 20 days for certain infections like early Lyme disease.

Procedural and Population Requirements

Oral tablets must be swallowed whole and should not be crushed, split, or chewed due to the persistent bitter taste and potential effects on drug release. In cases of renal impairment, official labeling mandates a change in dosing frequency, often extending the interval between doses (e.g., from every 12 hours to every 24 hours) based on measured kidney function. For intravenous administration, the medicine is typically given as a slow injection over 3 to 5 minutes or infused over 30 to 60 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefamar


Evidence for Use in Acute Respiratory and Ear Infections

The research for Cefamar (cefuroxime) in acute respiratory and ear infections focuses on study types such as Randomized Controlled Trials (RCTs) and comparative studies. For acute bacterial exacerbations of chronic bronchitis, research examined how patient-reported outcomes related to physical discomfort evolved over the short treatment duration. These trials also monitored microbiological outcomes, specifically the eradication of the bacteria causing the infection.

In research for Acute Otitis Media (ear infections), studies examined outcomes such as symptom intensity and clinical signs of infection, primarily in pediatric patients and adolescents. For conditions like acute sinusitis, research examined outcomes using an inactive comparison. Findings were mixed regarding changes measured in the patient groups, particularly in children.


Evidence for Specific Systemic Infections

Specific systemic infections evaluated in the research include early Lyme disease (the rash known as erythema migrans) and pharyngitis/tonsillitis. For early Lyme disease, clinical trials followed patients for extended periods, sometimes up to 12 months, to observe if any late-stage symptoms appeared. For pharyngitis/tonsillitis, studies monitored the bacterial eradication rate and clinical cure rate.


Research on Outcomes in Specific Age Groups

Research has included studies involving both adults and pediatric patients for most of its studied uses. However, data for certain groups remain insufficient, particularly for infants younger than 3 months of age, as studies involving this age group are not established in the research record.


Key Areas of Research Uncertainty and Gaps

Long-term outcomes are not well characterized for most acute indications, as follow-up durations were typically short. Furthermore, direct comparative evidence is lacking for some alternative antibiotic options, and available comparisons may be indirect. For certain acute infections like sinusitis, research has not demonstrated sufficient data for strains of bacteria that produce beta-lactamase enzymes, leaving a gap in understanding how Cefamar was studied against these specific resistant organisms.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Cefuroxime
  2. Cefuroxime: A comprehensive review of clinical trials
  3. Clinical efficacy of cefuroxime axetil versus penicillin V in the treatment of Group A beta-hemolytic streptococcal pharyngitis/tonsillitis
  4. Cefuroxime axetil for the treatment of community-acquired pneumonia in adults: a randomized, controlled trial

Frequently Asked Questions (FAQ)

Common questions about Cefamar (FAQ)


Q: What is Cefamar used for besides what is listed in the main section?

Official product information describes Cefamar as being indicated for treating a variety of bacterial infections. These include infections of the ear, throat, and sinuses, as well as those affecting the urinary tract and skin/soft tissue.


Q: Is Cefamar a type of antibiotic?

Yes, Cefamar is officially classified as a cephalosporin antibiotic. It belongs to this class of medicines that are used to fight bacterial infections.


Q: Why is Cefamar sometimes called a cephalosporin?

Cefamar is sometimes referred to by this name because it belongs to the cephalosporin class of antibiotics. This is the official classification given to the drug.


Q: What are the most common reasons a doctor prescribes Cefamar?

According to regulatory documents, Cefamar is prescribed to address certain bacterial infections. Common official indications include infections affecting the throat, ear, and sinuses, as well as specific infections of the lungs (bronchitis) and skin.


Q: How quickly should I expect Cefamar to start working?

Official drug information indicates that a patient typically begins to experience an improvement in symptoms during the first few days of treatment. If symptoms do not start to improve in this timeframe, a consultation with a healthcare provider is generally recommended.


Q: What happens if I stop using Cefamar suddenly?

Official drug information warns that stopping Cefamar suddenly or skipping doses may lead to the infection not being fully treated. This action may also increase the risk that the bacteria causing the infection could develop resistance to the antibiotic.


Q: Is Cefamar known to cause stomach upset?

Regulatory documents state that common side effects can include signs of stomach upset, such as nausea and vomiting. These effects are generally recognized in the official adverse reactions listing.


Q: Can Cefamar affect my sleep?

While not listed as a common effect, official reports have included less frequent side effects like drowsiness and a general feeling of sleepiness (somnolence). Patients should be aware of this potential effect on alertness.


Q: Is it true that Cefamar can cause allergic reactions?

Yes, official warnings emphasize that Cefamar, like other beta-lactam antibiotics, can potentially cause serious allergic reactions (hypersensitivity), which may occasionally be severe. The drug is contraindicated for anyone with a known allergy to it.


Q: Does Cefamar interact with common over-the-counter pain relievers?

Official documents list an interaction with the blood thinner warfarin. While specific common over-the-counter (OTC) pain relievers are not fully listed, OTC medicines like ibuprofen or aspirin can carry an increased bleeding risk if combined with blood thinners. Acetaminophen is generally considered safe in this context.


Q: Is Cefamar safe for older adults (seniors)?

The official product information suggests that caution may be necessary when Cefamar is used by older adults. This is particularly true for seniors with pre-existing kidney conditions, who may have a higher risk of certain neurological effects (neurotoxicity) associated with this class of drug.


Q: How is Cefamar usually stored?

The oral tablets are generally required to be stored at room temperature, typically between 20 C and 25 C (68 F to 77 F). Other forms of the medication, such as the oral suspension or injectable forms, will have their own specific storage instructions detailed on the official label.


Q: Does Cefamar cause dizziness or tiredness?

Regulatory information lists both dizziness and headache as common side effects of Cefamar. Additionally, effects like drowsiness and a general feeling of illness or discomfort have also been reported in clinical experience.


Q: Can I use Cefamar if I have a known allergy to penicillin?

Cefamar is contraindicated (should not be used) if a person has a known allergy to Cefamar itself, other cephalosporins, or other beta-lactam antibiotics. Official warnings note that a risk of cross-sensitivity may exist for individuals who have a history of penicillin allergy.


Q: What if I miss a scheduled dose of Cefamar?

Patient information leaflets generally describe a procedure to follow for a missed dose. Official guidance often involves skipping the dose if it is nearly time for the next one to help prevent taking a double dose. This specific procedure is detailed in the patient information leaflet.


Q: Is Cefamar generally considered safe to use during pregnancy?

Regulatory safety information states that there are not enough well-controlled studies in pregnant women to determine if the drug poses a definitive risk to the fetus. Therefore, the use of Cefamar during pregnancy is a matter for consultation and determination by a healthcare provider.


Q: What is the risk of Cefamar causing diarrhea?

Diarrhea is listed as a common side effect associated with Cefamar. Official warnings state that while typically mild, in some instances, diarrhea can become severe and persistent, which may require evaluation by a healthcare provider for Clostridioides difficile-associated diarrhea (CDAD).


Q: What happens if I drink alcohol while using Cefamar?

Official documents do not typically list a direct, widely documented negative interaction between Cefamar itself and alcohol. However, a discussion about alcohol use with a healthcare provider is generally recommended, especially if the patient is taking concurrent medications, like the blood thinner warfarin, where excessive alcohol can increase the risk of bleeding.


Q: Does Cefamar make you feel generally unwell?

Regulatory reports on adverse reactions have included a general feeling of illness or discomfort as a reported side effect of the medication. This is sometimes described as malaise.


Q: Is it normal to feel a metallic taste after using Cefamar?

Yes, official side effect listings have included reports of an unusual, bad, or unpleasant taste or a change in taste as a less common event. This may manifest as a metallic taste for some individuals.


Q: Does Cefamar interact with blood thinners like warfarin?

Yes, the official interaction information indicates that Cefamar may increase the effects of certain blood thinners, such as warfarin. This combination can potentially lead to an increased risk of bleeding, a situation which a healthcare provider would typically manage with specific monitoring.


Q: Is Cefamar known to cause yeast infections?

Yes, official warnings state that Cefamar use may lead to the overgrowth of non-susceptible organisms, which includes the yeast Candida. This overgrowth can potentially result in the development of vaginal yeast infections or oral thrush.


Q: Are headaches a common side effect of Cefamar?

Yes, regulatory reports on adverse reactions list headache as a common side effect associated with Cefamar.


Q: Can Cefamar affect liver enzyme levels?

Official side effect profiles have reported that transient liver enzyme elevations (temporary changes in blood test values that measure liver function) can occur as a less common reaction to the drug.


Q: Can Cefamar cause confusion or mental fogginess?

In rare instances, particularly in patients with pre-existing kidney problems, Cefamar has been associated with signs of neurotoxicity (effects on the nervous system). Symptoms that have been reported include confusion or a feeling of mental fogginess.


Q: Are there common signs that Cefamar is not working for an infection?

Official patient information advises that if symptoms of the infection do not begin to improve within the first few days of taking the medication, or if they become worse, this is a situation that warrants reporting to a healthcare provider.


Q: What should I do if my symptoms get worse while using Cefamar?

The official guidance indicates that if your infection symptoms worsen while using Cefamar, or if they fail to improve after the first few days of treatment, immediate contact with a doctor or healthcare provider is advised.


Q: What color are the Cefamar tablets/capsules usually?

Cefamar tablets are typically film-coated and may be described by their color (e.g., blue or white) and any specific engraving on the pill, which varies based on the manufacturer and the specific formulation of the drug.


Q: Are certain medical conditions listed as contraindications for Cefamar?

Yes, the regulatory profile lists hypersensitivity (allergic reactions) to Cefamar itself, other cephalosporins, or any other beta-lactam antibiotics as a contraindication. A contraindication means the drug should not be used under that condition.


Q: Is Cefamar used for skin and soft tissue infections?

Yes, official indications for Cefamar include the treatment of certain types of uncomplicated skin and soft tissue infections.


Q: What kind of infections is Cefamar typically not effective against?

Cefamar is an antibiotic designed to treat bacterial infections and, as such, regulatory information confirms it will not work for viral infections like the common cold or flu. Using it when there is no bacterial infection present may contribute to the development of drug-resistant bacteria.

How should Cefamar be stored and disposed of?

How to Store and Dispose of Cefamar?

The storage requirements for Cefamar (Cefuroxime) are mandated by its formulation.

Storage Requirements

Form Temperature Requirement Stability After Mixing
Tablets/Dry Powder Not exceeding 30 C N/A
Oral Suspension (Reconstituted) le 30 C 7 days
Oral Suspension (Refrigerated) 2 C to 8 C 14 days

The powder for injection must be stored below 25 C and protected from light by remaining in its outer carton. Specific instructions prohibit refreezing thawed solutions and recommend against using sodium bicarbonate for dilution.

Disposal

Any unused reconstituted product must be discarded after the specified stability period has elapsed. Disposal of expired or unused Cefamar must be completed in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefamar found in:

A-Z Index: